Clinical Trial Update: EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for EVOlocumab in acute coronary syndrome assessing early reduction of LDL-cholesterol levels.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Acute Coronary Syndrome | Phase 3 | Status: COMPLETED